Dynavox Group AB reported solid Q2 2026 results with revenue up 11% to SEK670 million and a gross margin of 70%, driven by broad demand for its assistive communication solutions. Operating profit more than doubled, lifting the EBIT margin to 15.7% and pushing net profit to SEK74 million with earnings per share around SEK0.70, supported by a streamlined, digitized platform and ongoing integration of acquisitions. For the first half of 2026, revenue rose 6% to SEK1,257 million with currency-adjusted growth of 16%, while cash flow improved as investments continued and acquisitions contributed to growth. Management reaffirmed long-term targets of 20% average annual revenue growth in constant currency and an EBIT margin of at least 15%, noting currency effects and the continued integration of European acquisitions. The company highlighted strong underlying demand across geographies, ongoing challenges in prescription processes, and rising component costs, while completing the SR Labs Healthcare acquisition in Italy and referencing a U.S. study on the social value of comprehensive assistive communication. Overall, the results point to a scalable, diversified healthcare technology business positioned for continued growth.